Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) yesterday and set a price target of $70.00. The company’s shares closed yesterday at $86.00.
Lawson covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Exelixis, and Iovance Biotherapeutics. According to TipRanks, Lawson has an average return of 10.5% and a 46.69% success rate on recommended stocks.
Blueprint Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $92.50.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $94.47 and a one-year low of $37.82. Currently, Blueprint Medicines has an average volume of 845.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines (BPMC) Company Description:
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Read More on BPMC:
- Blueprint Medicines Divests GAVRETO Rights to Rigel
- Blueprint Medicines price target raised to $97 from $92 at Needham
- Blueprint Medicines price target lowered to $107 from $115 at Wells Fargo
- Blueprint Medicines price target raised to $65 from $54 at Citi
- Blueprint Medicines price target raised to $125 from $85 at H.C. Wainwright
